Loading...
Loading...
Also known as: GRF 1-29, GHRH 1-29
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.
Benefits
6
Conditions
5
Evidence
Clinical trials, formerly FDA approved+ studies
Source
Synthetic GHRH fragment (amino acids 1-29)
Gabriel Brain Score
Moderate
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.
Binds GHRH receptors to stimulate endogenous GH secretion, preserves natural pulsatile GH patterns, short half-life requires more frequent dosing, maintains hypothalamic-pituitary feedback loops.
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Clinical trials, formerly FDA approved
Previously FDA approved for pediatric GH deficiency. Evidence supports GH elevation and IGF-1 increase. Used off-label for anti-aging despite FDA discontinuation of original approval for commercial reasons.
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Potent hexapeptide ghrelin mimetic with strong GH-releasing effects and cardioprotective properties.
Long-acting GHRH analog that stimulates sustained growth hormone release.